David A. Siegel Rhythm Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 13,100 shares of RYTM stock, worth $808,794. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,100
Previous 12,800
2.34%
Holding current value
$808,794
Previous $670,000
9.25%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding RYTM
# of Institutions
219Shares Held
64.5MCall Options Held
445KPut Options Held
26.6K-
Black Rock Inc. New York, NY6.74MShares$416 Million0.01% of portfolio
-
Primecap Management CO Pasadena, CA6.57MShares$406 Million0.29% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$376 Million5.51% of portfolio
-
Baker Bros. Advisors LP New York, NY6.08MShares$376 Million3.77% of portfolio
-
Perceptive Advisors LLC New York, NY3.68MShares$227 Million6.86% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $3.44B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...